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INTRODUCTION
Since first introduced by Stein and Leventhal in 1935,
Polycystic Ovarian Syndrome (PCOs) is one of the
leading endocrinology problem found in women and
caused infertility due to anovulation.1
Polycystic ovaries were found in 73% infertility
cases with anovulation, in 37% women with amenor-
rhea and in 90% women with oligomenorrhea.2 To
find the etiology and understand the pathophysiology
of PCOs might help us to figure out the most appro-
priate management.
Abstract
Objectives: To find 5-untranslated region polymorphism of
CYP17 gene and its connection with hyperandrogenemia in poly-
cystic ovarian syndrome.
Methods: A cross sectional descriptive study with consecutive
random sampling method. Body mass index, ovarian morphology by
ultrasonography, fasting insulin level, fasting blood glucose level,
17-hydroxyprogesterone level, total testosterone level, serum hor-
mone binding globulin level, and CYP17 gene polymorphism in 45
subject with PCOs and 45 control subject who attend Yasmin clinic
of Cipto Mangunkusumo General Hospital with menstruation pro-
blems were measured. CYP17 gene polymorphism was evaluated
using polymerase chain reaction-restriction fragment length poly-
morphism (PCR-RFLP) method with MspA1 restriction enzyme.
Results: In PCOs group, the genotype distribution were; 11.1%
subject with genotype CC, 71.1% subject with genotype TC and
17.8% subject was wild type TT. In non PCOs group, the genotype
distribution for CC, TC and TT respectively were 13.3%, 46.7% and
40%. There was significant difference between both group in distri-
bution of TC and TT genotype, with p value 0.013. Frequencies of
allele c and allele t in PCOs group were 47% and 53%. In non PCOs
group, frequency of allele c and t were 37% and 63%. There were
tendency for higher frequency of allele c in the PCOs group but the
difference was not statistically significant. Median FAI value for
genotype CC homozygote, TC heterozygote and TT homozygote in
PCOs group respectively were; 6.82 (6.07 - 8.23); 5.59 (0.25 -21.45)
and 4.74 (3.48 - 8.88). There was tendency for increase FAI value
in PCOs group corresponds to variant allele, but the result was not
statistically different.
Conclusion: There were higher proportion of CC homozygote
and TC heterozygote genotype in PCOs patient with tendency of in-
creasing FAI value.
[Indones J Obstet Gynecol 2011; 35-1: 3-7]
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Abstrak
Tujuan: Mengetahui prevalensi polimorfisme CYP17 pada 5-
UTR dan hubungan antara polimorfisme CYP17 dengan hiperan-
drogenemia pada sindrom ovarium polikistik.
Metode: Penelitian deskriptif dengan studi potong lintang. In-
deks massa tubuh, penilaian ovarium, kadar hormon LH/FSH, insu-
lin puasa, gula darah puasa, 17 hidroksi progesteron, testosteron
total, SHBG dan polimorfisme CYP17 dinilai pada 45 subjek SOPK
dan 45 subjek kontrol yang datang ke klinik Yasmin RSCM dengan
keluhan haid. Pemeriksaan polimorfisme CYP17 dilakukan dengan
PCR RFLP dengan menggunakan enzim restriksi MspA1.
Hasil: Pada kelompok SOPK didapatkan genotip CC pada 5
(11,1%) subjek, genotip TC 32 (71,1%) subjek dan genotip TT pada
8 (17,8%) subjek. Pada kelompok non SOPK, jumlah subjek de-
ngan genotip CC, TC dan TT berturut-turut 6 (13,3%), 21 (46,7%),
dan 18 (40%). Pada perbandingan antara kelompok homozigot CC
dengan wild type TT didapatkan hasil yang tidak bermakna secara
statistik dengan nilai p 0,392. Hasil yang bermakna dilihat dari per-
bandingan antara kelompok heterozigot TC dengan wild type TT,
dengan nilai p 0,013. Pada kelompok SOPK, ditemukan frekuensi
alel c sebesar 47% dan frekuensi alel t 53%. Sedangkan pada
kelompok non SOPK frekuensi alel c adalah 37% dan frekuensi alel
t 63%. Terdapat kecenderungan peningkatan frekuensi alel c pada
kelompok SOPK dibandingkan dengan kelompok non SOPK namun
hasil tersebut tidak bermakna secara statistik dengan nilai p 0,1.
Didapatkan hasil median kadar FAI dari kelompok homozigot CC,
heterozigot TC dan wild type TT SOPK berturut-turut adalah 6,82
(6,07 - 8,23); 5,59 (0,25 - 21,45) dan 4,74 (3,48 - 8,88). Terdapat
kecenderungan peningkatan nilai FAI pada kelompok genotip ho-
mozigot CC dan heterozigot TC, namun hasilnya tidak bermakna se-
cara statistik dengan nilai p 0,468.
Kesimpulan: Proporsi genotip CC dan TC lebih tinggi pada
pasien SOPK dan terdapat kecenderungan peningkatan nilai FAI
pada kelompok homozigot XX dan heterozigot TC, namun hasil
tersebut tidak bermakna secara statistik.
[Maj Obstet Ginekol Indones 2011; 35-1: 3-7]
Kata kunci: sindrom ovarium polikistik, free androgen index,
polimorfisme CYP17
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The diagnosis of PCOs was confirmed if there were
2 out of 3 conditions below; oligomenorrhea or
anovulation, clinical sign or biochemistry of hyperan-
drogenemia and polycystic ovary seen by ultrasono-
graphy.3 The prevalence of PCOs using this criteria
was 22% with incidence in the reproductive age wo-
men is 1 out of 12.4
PCOs was a cohort of signs and symptoms which
lead to reproductive, endocrinology and metabolic
disturbance. The patophysiology was considered mul-
tifactorial and polygenic.5 From many studies, the
leading hypothesis were disturbance in insulin secre-
tion and action regulator gene; disturbance in follicu-
logenesis regulator gene (gonadotropin regulator ge-
ne); weight and energy regulator gene; and androgen
secretion and action regulator gene. Any disturbance
in those genes will cause clinical manifestation of
PCOs.3,6
Even though considered caused by multifactorial
etiology, one of the patophysiology and included into
the diagnostic criteria is hyperandrogenemia.2,7 As
stated before disruption in androgen synthesis gene
might result in androgen hormone level abnormality.
Many gene candidates were thought to be responsible
in regulation of androgen biosynthesis. Urbanek et al
found 8 genes related to hyperandrogenemia in PCOs,
one of them is CYP17 gene.8 Rate of androgen bio-
synthesis was depend on 17-hydroxylase/17,20 lyase
enzyme activity (also known as CYP17). This enzyme
is family of cytocrome P450, coded by CYP17 gene
that located in chromosome 10q24,3. CYP17 acted
through 17α-hydroxylase activity will convert 17α-
hydroxypregnenolone into cortisol. When 17α-hydro-
xylase and 17,20-lyase were activated, dehydroepian-
drosterone (DHEA) will be produced. The DHEA will
then be converted into androstenedione by 3ßHSD II
enzyme activity. Androstenedione will be converted
to testosterone and estradiol by isoenzyme 17ß-hy-
droxysteroid dehydrogenase and aromatase.6,9,10
Through this androgen biosynthesis pathway, CYP17
considered as having an important role.
Study in ovarian theca cell found an enhancement
of expression and activity of CYP17 gene in PCOs
women. Numerous factors affecting CYP17 gene ac-
tivity in PCOs, one was stated by Carey at al; there
was variant allele in CYP17 gene.8
Until recently, one of CYP17 variant allele that has
been found is single nucleotide polymorphism T→C
in 5’-untranslated region (5-UTR). This polymor-
phism will create new promoter, enhance CYP17 ac-
tivity and consecutively increase the androgen biosyn-
thesis rate. Polymorphism in 5-UTR will create new
variant with genotype TC heterozygote and CC ho-
mozygote.6 Diamanti et al shows an increased total
testosterone level in TC heterozygote compared with
the wild type genotype.
Previous study linked CYP17 polymorphism with
hyperandrogenemia using androstenedione or total
cholesterol for measuring hyperandrogenemia. Unfor-
tunately, total testosterone level could not show tes-
tosterone bioavailability due to the influence of serum
hormone binding globulin (SHBG) level. Free andro-
gen index (FAI) could be more accurate in showing
free testosterone level in blood. This FAI was calcu-
lated from total testosteron divided by SHBG. This
study will evaluate hyperandrogenemia with the pa-
rameter of an increased FAI due to CYP17 polymor-
phism.
METHODS
The study was conducted after FKUI ethical commis-
sion approval and the sample was collected from July
to October 2010. This was a descriptive with com-
parative cross sectional study.
Subject was chosen with consecutive random sam-
pling. The study population were patients coming to
YASMIN clinic at Dr. Cipto Mangunkusumo General
Hospital with the diagnosis of PCOs and as control
are patients with other problems. The sample was
chosen with simple random sampling. Patient with hy-
perandrogenemia due to congenital adrenal hyper-
plasia were excluded.
Calculated sample size using 0.15 as d constanta
was 45 subject. Prior to signing the consent, subjects
were informed. Interview was conducted regarding
the basic data, followed by physical examination in-
cluding BMI, and transvaginal ultrasonography.
Sample collection for laboratory examination (LH,
FSH, fasting blood glucose, fasting insulin, total cho-
lesterol, SHBG and CYP17 polymorphism) was con-
ducted in day 3 - 5 of cycle in patient with regular
cycle and in any days for patient with irregular men-
struation.
Isolation of DNA genome for genotype analysis
was taken from peripheral blood sample using DNA
genomarker kit extractor (Blossom, Taiwan). Primers
used in DNA amplification were forward primer 5’-
CAT-TCG-CAC-TCT-GGA-GTC-3’ and reverse pri-
mer 3’-AGG-CTC-TTG-GGG-TAC-TTG-5’ (Eurogen-
tec AIT).
Five μl of DNA genome (extracted from leucocyte
using QIAamp DNA Mini and Bllod Mini Kit) added
to 20 μm of every primers, 1.5 mM MgCl2, 0.2 mm
deoxyribonucleotide triphosphate and 0,1 U AmpliTaq
polymerase DNA (Invitrogen.Cat.No.10966-018).
ThermalCycler (PE2400) was used for amplifica-
tion with total 35 cycle in heat condition 94°C for 3
minutes, 94°C for 30 seconds, 55°C for 30 seconds,
72°C for 1 minute and 72°C for 5 minutes.
Amplicon was digested for one hour using 0.5 μl
MspA1 I (AIT). Restriction fragment lenght polymor-
phism (RFLP) analysis was conducted using electro-
phoresis in 2% agarose gel. The endonuclear genotype
is considered as "T" if there was no restriction site
and stated as "C" when there was a restriction site.
Amplicon with 414-bp was restricted by MspA1
enzyme to two band sized 290-bp and 124-bp. Homo-
zygote TT/wild type will be seen as single band sized
414-bp. Homozygote CC will be seen as dual band
sized 290-bp and 124-bp. While the heterozygote TC
will be seen as three bands sized 414-bp, 290-bp and
124-bp.
Genotype frequencies and allele in both group and
in between different genotype will be calculated and
compared.
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RESULT
Sample collection was conducted from July 2010 to
October 2010. Research sample consists of 45 res-
ponders for each group.
Mean age of each group were comparable. Medical
data of nutritional status (body mass index), insulin
resistance, testosteron level and free androgen index
from both group were compared.
From PCOs group 60% of the subject were con-
sidered as obese. Insulin resistance was found in 67%
subject in PCOs group while in non PCOs group, only
12% were considered having insulin resistance.
Adrogen profile of both group were measured us-
ing testosteron level and FAI. (see Table 1)
Table 1. Androgen profile in both group.
Androgen level PCOs Non PCOs p value
Testosterone
(nmol/l)
130,77
(6,95 - 489,42)
65,90
(9,91 - 199,39)
0,000
FAI   6,07
(0,25 - 21,45)
 1,87
(0,24 - 5,00)
0,000
Median total testosterone level and FAI were
higher in PCOs group, and the results were statisti-
cally significant with p value 0.000.
CYP17 Genotype, Molecular Analysis
The amplicon from PCR has sequence as showed in
Figure 1.
The arrow was marking the restriction site that
would be recognized by MspA1 restriction enzyme.
In DNA sample with CYP17 polymorphism, the
sequens CAG CAG will change into CAG CGG and
will be recognized by MspA1 I restriction enzyme.
Using electrophoresis in agarose 2% gel, the genotype
of DNA sample will be known. Sample with TT ho-
mozygote genotype will be seen as one band; sample
with CC homozygote genotype will be seen having
dual band while TC heterozygote genotype shown as
three bands. (see Figure 2)
Sample number 6, 12, 13, 20 and 68 are 414-bp
DNA showing TT homozygote genotype. Sample
number 11 and 24 are 290-bp and 124-bp DNA frag-
ment showing CC homozygote genotype and the rest
are TC heterozygote genotype consist of 414-bp, 290-
bp and 124-bp DNA fragment.
Result for genotype and allele frequencies in both
group were mentioned below.
In PCOs group the genotype were 11.1% was CC
homozygote, 71.1% was TC heterozygote and 17.8%
was TT homozygote. While in non PCOs group the
genotypes for CC, TC and TT consecutively were
13.3%, 46.7% and 40%. A statistically significant re-
sult (p value 0.013) was shown when we compared
the heterozygote TC and wild type TT between both
group, while result of comparison from homozygote
CC and wild type TT showed no significant difference
(p value 0.392).
For allele frequencies; in PCOs group allele c was
found in 47% subject and allele t frequency was 53%,
while in non PCOs group frequency of allele c and t
consecutively were 37% and 63%. There were ten-
dency of increasing allele c frequency in PCOs group
but the result was not statistically significant (p value
0.1).
Relationship between CYP17 genotype and andro-
gene level were shown in Table 2.
Total testosterone level tend to increase in CC ho-
mozygote compared with TC heterozygote and TT ho-
mozygote. Median testosterone level were 10.84% in-
creased in CC homozygote compared with TT ho-
mozygote.
Table 2. Relation of CYP17 genotype in PCOs group with to-
tal testosterone level and FAI.
Geno
type
PCOs
n FAI
Testosterone
nmol/l
CC  5 6,82 
(6,07 - 8,23)
145,92
(129,65 - 489,42)
TC 32 5,59 
(0,25 - 21,45)
120,23
(6,95 - 282,49)
TT  8 4,74 
(3,48 - 8,88)
131,65
(83,97 - 276)
p 0,468 0,394
Hyperandrogenemia also assessed using FAI. The
FAI also tend to be increased in CC homozygote and
TC heterozygote group but the result was not statis-
tically different.
DISCUSSION
The main patophysiology for PCOs was still a mys-
tery need to be solved. The complex clinical signs
AGG CTT 
GCT GTA TCC 
GCT GCA TAG TAG TGT 
GGC AGG GGC CTT TTA GGC TAC CCT CTT 
CTT GTG CTT GCC TTG TGG TCT CCT 
CTG TCA TAT GCG GTG 
GTG GCC GCT TCA ACC TCC 
TGC TTG GTG CGA ATG 
GCT GGG TCA GTT CCT CTG 
Figure 1. Amplicon from PCR.
Figure 2. Detection of 5’-UTR CYP17 polymorphism with
PCR-RFLP using MspA1 I restriction enzyme.
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and symptoms needs to be explained by understan-
ding the different patophysiological mechanisms.
Four main theories discussed worldwide were1 an-
drogene synthesis defect result in increasing ovarian
androgene hormone production;2 disturbance in insu-
lin secretion and action caused hyperinsulinemia and
insulin resistance;3 primary neuroendocrine defect
caused increasing LH frequency and amplitude; and4
cortisol metabolism changes caused adrenal androge-
ne production.11
Ovarian steroid biosynthesis depend on several
chemical reaction, started with cholesterol transloca-
tion to inner membrane of mitochondria regulated by
steroidogenic acute regulatory protein and continued
with steroidogenesis process in ovarian theca cell. Nu-
merous genes were involved in regulation of steroid
biosynthesis, such as CYP17, CYP11A (P450 choles-
terol side chain cleavage enzyme) and 3ß-hydroxys-
teroid dehydrogenase.6
CYP17 gene is located in chromosome 10q24.3
which coded cytocrome enzyme P450c17α with 17α-
hydroxylase and 17,20-lyase activity. This enzyme
will convert pregnenolone and progesterone into 17-
hydroxypregnenolone and 17-hydroxyprogesterone and
continued with convertion of both form of steroid into
dehydroepiandrosterone and androstenedione.1 Pre-
vious study in ovarian theca cell of PCOs patient
found an increased CYP17 gene transcription and
cAMP dependent. Other study found a single nucleo-
tide polymorphism T/C in promoter region resulting
in increase of CYP17 activity.8
Carey et al in 1994 found increasing risk to have
PCOs in person with variant allele. This variant allele
connected with androgen hormone increasing.8
Until now, 3 CYP17 gene polymorphism already
found; T/C mutation in 5’-UTR, G/A mutation in pro-
moter region of nucleotide 1951 and T/A mutation in
5471 nucleotide.
Polymorphism in 5’-UTR create variant allele with
new promoter. Amount of promoter correlate with
promoter activity. So this variant allele were consi-
dered to cause transcriptional increase. Increasing
transcription will cause increasing activity and con-
tinued with increasing androgen level in the ovary
with the end result was ceased of follicle matura-
tion.12
Insulin resistance prevalence were higher in the
PCOs group. Peripheral insulin resistance will in-
crease the plasma insulin level. Insulin will bound to
IGF-1 and together increase theca cell androgen pro-
duction under the influence of luteinizing hormone.
Insulin will also decrease liver SHBG production,
caused increasing testosteron bioavailability due to in-
creasing plasma free testosterone level.
Hyperandrogenemia was classified with total tes-
tosterone level and FAI. Total testosterone level and
FAI in PCOs group were higher than control group
and the difference was statistically significant.
For 5’-UTR CYP17 polymorphism; in this study
we found higher variant allele frequency among the
PCOs group. The allele c frequency were 10% higher
in PCOs group (47% to 37%). TC heterozygote geno-
type was found in 71% subject in PCOs group and
CC homozygote genotype frequency was 11%.
Different result coming from different population.
CC homozygote frequency were higher in population
with East Asian origin. Study in Singaporean, Tai-
wanese, Asian ethnic or India-Pakistan ethnic who
lived in Canada showed CC homozygote frequency
32%. Smaller frequency were found among white skin
population in North America, Europe and Australia;
with CC homozygote frequency were 14%. In Russia,
frequency for CC homozygote were 23 - 25%. One
study in Nigeria, Africa found 9% CC homozygote
frequency.12
In this sudy we compare the frequency of CC ho-
mozygote in both groups; frequency of TC heterozy-
gote and CC homozygote were lower in non PCOs
group. This shows tendency for varian gene with T/C
polymorphism caused increase androgen synthesis.
Data about subject’s ethnic should be included in
genetic study. Indonesia is a country with many eth-
nical diversity with different characteristics. Many
ways to classify ethnic groups were used. One of them
is differentiating ethnic group based on parental ori-
gin; with austronesia if the patient came from Java,
Borneo and Bali; Wallace if the patient came from
Sulawesi and Sumbawa; and Papua for subjects from
Papua. Limitation of this study is that we did not in-
clude ethnic group in the data.
In this study we found that variant allele will in-
crease risk for having PCOs. Results from this study
are consistent with many previous studies. We are
using FAI to measured androgene hormonal status.
This index shows testosterone bioavailability and
spesifically shows androgene abnormality. In PCOs
group the median FAI score were 20.6% higher in
TC heterozygote group compared with TT homozy-
gote and 29.4% higher in CC homozygote group com-
pared with TT homozygote.
Other study using other measurement method to
assess androgene status for subject with CYP17 poly-
morphism. Diamanti et al compared testosterone level
in TT homozygote with heterozygote, with result 15%
higher testosterone level in homozygote group.13 Hai-
man et al compared testosterone, androstenedione,
DHEA and DHEAS level between genotype and
found; 6% higher of testosterone level (p = 0.40), 5%
higher of androstenedione level (p = 0.47), 2% higher
of DHEAS level (p = 0.82) and 7% higher of DHEA
level (p = 0.47) in CC homozygote compared with
the wild type.14 Other study from Daneshman et al
compared testosterone plasma level and andros-
tenedione in follicle fluid, they found 2% higher tes-
tosterone level and 40% higher androstenedione level
in TC heterozygote compared with TT homozygote.15
Garcia-Closas also found higher mean andros-
tenedione and testosterone level in CC homozygote
compared with TC heterozygote and TT homozygote;
androstenedione level were 0.3% higher in TC het-
erozygote compared with CC homozygote and testos-
terone level were 4% higher.16
Different result came from non PCOs group. The
FAI in CC homozygote were lower than TT homozy-
gote. We previously thought that CYP17 polymor-
phism in non PCOs group was not related with in-
creasing androgen production. Many factors contri-
butes in steroid metabolism.
First we thought about other mutation site in CYP
gene. Until now we have already found 3 point of
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mutation; T/C polymorphism in 5’-UTR region; G/A
mutation in nucleotide 1951 or promoter region; and
C/A mutation in nucleotide 5471.12 Increasing activity
of CYP17 enzyme might be caused by one of those
mutation or if there were two mutations in the same
individual. Whether one point of mutation is having
higher influence than other need to be proven in fol-
lowing study.
The second factor is the presence of phosphoryla-
tion which influence CYP17 enzyme activity. Human
CYP17 will through serine and treonine phosphory-
lation via cAMP-dependent protein kinase. CYP17
phosphorylation will increase 17.20-lyase activity and
dephosphorylation will decrease it. Lin-Hua Zhang
concluded that cAMP dependent mechanism in adre-
nal gland and other kinase dependent mechanism in
ovarium will cause CYP17 phosphorylation. In addi-
tion, abnormality of LH secretion in PCOs patient
may cause an impairment of serine phosphorylation.
Serine phosphorylation in insulin receptor also cause
insulin resistance.17,18 Further studies are needed to
explain the relationship between serine phosphoryla-
tion, CYP17 polymorphism and hyperandrogenemia.
Several other genes and enzymes take part in con-
trolling steroid biosynthesis. Those agents are; Cy-
tocrome P450scc or known as CYP11a which control
the production and responsible for 17-hydroxypro-
gesterone conversion to 11-deoxycortisol; aromatase
gene responsible for conversion of C19 steroid to C18
steroid.19,20 Probability of mutation and interaction
among those genes in causing impairment of steroid
metabolism needs further studies.
Another explanation is a complexity of CYP17
promoter activity. In adrenal cortex, building protein
structure started with stimulation of adrenocorticot-
ropin (ACTH) to activate steroidogenic gene promo-
ter. Some transcription factors were already known to
cause disruption in promoter activity. Those are; ste-
roidogenic factor-1 (SF-1), GATA-6 and sterol regu-
latory binding protein 1 (SREBP1).21 Those trans-
cription factors part in disrupting androgen biosyn-
thesis also need to be explored further.
CONCLUSION
This study found a higher proportion of CC and TC
genotype in PCOs patient and the tendency of increas-
ing free androgen index level in patients with geno-
type CC homozygote and TC heterozygote. 
Further study about interaction of CYP17 polymor-
phism with other gene and other factor that impaired
CYP17 activity with end result androgen elevation
should be conducted with a larger sample size and
adding an ethnical analysis.
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